Table 1 Patients demographic, functional, treatment and blood characteristics
From: Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis
Healthy subjects n = 55 | Untreated IPF n = 24 | Treated IPF n = 26 | |
|---|---|---|---|
Age, yrs | 60 (8) | 74 (9)*** | 68 (9)*** |
Gender (M/F) | 28/27 | 19/5 | 16/3 |
Height, cm | 170 (8) | 168 (10) | 170 (9) |
Weight, Kg | 75 (12) | 74 (16) | 78 (11) |
BMI, Kg/m2 | 26 (3) | 26 (4) | 27 (3) |
Smokers (NS/FS/S) | 23/22/6 | 3/8/6 | (6/19/0) |
Leucocytes x103/μl | 7.00 (5.39) | 8.35 (2.35)* | 8.42 (2.91)** |
Neutrophils (Cell/μl) | 3450 (1025) | 5614 (2113)*** | 5960 (3053)*** |
Lymphocytes (Cell/μl) | 2085 (620) | 1676 (825)* | 1786 (643) |
Monocytes (Cell/μl) | 486 (160) | 698 (325)** | 725 (218)*** |
Eosinophils (Cell/μl) | 173 (125) | 314 (266)** | 214 (128) |
Basophils (Cell/μl) | 33 (17) | 55 (67) | 94 (187) |
Fibrinogen (g/l) | 3 (0.80) | a4 (1.40)*** | nd |
CRP (mg/l) | 1.9 (2.89) | a30 (37.89)*** | nd |
FEV1 post-BD, %pred. | 105 (12) | 75 (14)*** | 67 (13)*** |
FVC post-BD, %pred. | 111 (16) | 73 (14)*** | 66 (16)*** |
TLC, %pred. | nd | 71 (19) | 68 (15) |
DLCO %pred. | nd | 37 (11) | 38 (13) |
KCO %pred. | nd | 63 (16) | 70 (20) |
Treatment (pirfenidone/nintedanib) | 0/0 | 0/0 | 17/9 |
Pirfenidone (duration of treatment -Month) | nd | nd | 9.9 (7.4) |
Nintedanib (duration of treatment -Month) | nd | nd | 14.3 (15.8) |